{"id":181282,"name":"BIOTECHNOLOGY INDUSTRY ORGANIZATION","slug":"biotechnology-industry-organization","state":"DC","description":null,"totalSpending":2240000,"filings":28,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":320000},{"year":2020,"income":240000},{"year":2021,"income":400000},{"year":2022,"income":400000},{"year":2024,"income":320000},{"year":2025,"income":320000}],"firms":["TARPLIN, DOWNS & YOUNG, LLC"],"lobbyists":["RAISSA DOWNS","JENNIFER YOUNG","MICHELLE EASTON","ELIZABETH MURRAY","CHARLOTTE IVANCIC","PAMELA SMITH","EMILY MURRY","KIMBERLY BRANDT","MARGARET JOSEPH","PETER FISE","LAURA FRIEDEL","PARICK CARROLL"],"issues":["PHA","MMM","TAX","HCR","BUD"],"sampleDescriptions":["PL 114-255 - 21st Century Cures, implementation\nH.R. 2430 - FDA Reauthorization Act of 2017\n\n\n***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation","Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D Non-Interference, health care reform, biosimilars, 340B, Sunshine, discount cards, MedPAC, coding, ASP, Part B, donut hole, Part D cliff, prescription drug access and affordability\nS. 870 - Chronic Care\nH.R. 3921 - Healthy Kids Act\nS. 1827 - Kids Act of 2017\nS. 260/H.R. 849 - Protecting Seniors' Access to Medicare Act of 2017","pharmaceutical tax, orphan drug tax credit","PL 114-255 - 21st Century Cures, implementation\nS. 456 - RACE for Children Act\nS. 771 - Improving Access to Affordable Prescription Drugs Act\nS. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017\nStopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017\nS. 469 - Affordable and Safe Prescription Drug Importation act\nH.R. 749 - Lower Drug Costs Through Competition Act\nH.R. 878/S. 204 - Right to Try Act of 2017\nH.R. 1480/S. 64/S. 92 - Safe and Affordable Drugs from Canada Act of 2017\nH.R. 2430 - FDA Reauthorization Act of 2017\nH.R. 6 - SUPPORT for Patients and Communities Act\nS. 3120 - HEAL Substance Use Disorders Act\nS. 2680 - Opioid Crisis Response Act\nS. 2852 - Pandemic and All Hazards Preparedness Act \n\n\n***, no specific bill(s), health care reform, Biosimilars, PDUFA and related FDA policies, Innovation, 340B, comparative effectiveness research, user fee reauthorization, non-interference, IPAB","budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations\nH.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\n2019 Appropriations","budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations\nH.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\nH.R. 6157 - HHS appropriations and continuing resolution","budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations\nH.R. 1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018\nH.R. 6157 - HHS appropriations and continuing resolution\nH.R. 695 - Department of Defense Appropriations Act","Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D Non-Interference, health care reform, biosimilars, 340B, Sunshine, discount cards, MedPAC, coding, ASP, Part B, prescription drug access and affordability, transparency\nH.R. 1839 - Medicaid Services Investment and Accountability Act of 2019","budget resolution, reconciliation, deficit reduction, debt ceiling, appropriations\nH.J.Res. 31 - Consolidated Appropriations Act, 2019","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\n\nno specific bills, health care reform, Biosimilars, PDUFA and related FDA policies, Innovation, 340B, comparative effectiveness research, user fee authorization, non-interference, opioids","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation, transparency","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \nS. 1895 - Lower Health Care Costs Act \n\nno specific bills, health care reform, Biosimilars, FDA policies, Innovation, 340B, comparative effectiveness research, non-interference, opioids","deficit reduction, debt ceiling, appropriations\nH.R. 2740 - HHS Appropriations, 2020\nH.R. 3164 - FDA Appropriations, 2020","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\nS. 1895 - Lower Health Care Costs Act\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency","deficit reduction, debt ceiling, appropriations\nH.R. 2740 - HHS Appropriations, 2020\nH.R. 3164 - FDA Appropriations, 2020\nH.R. 4378 - Continuing Appropriations Act and Health Extenders Act","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \nS. 1895 - Lower Health Care Costs Act \nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\n\nno specific bills, health care reform, Biosimilars, FDA policies, Innovation, 340B, comparative effectiveness research, non-interference, opioids","Medicare and Medicaid Drug Reimbursement, Medicaid Rebate, Medicare Part D Non-Interference, health care reform, biosimilars, 340B, Sunshine, discount cards, MedPAC, coding, ASP, Part B, prescription drug access and affordability, transparency, international reference pricing, Stark & anti-kickback policies\n\nH.R. 1839 - Medicaid Services Investment and Accountability Act of 2019","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\nS. 1895 - Lower Health Care Costs Act\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\n\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency","H.R. 1781 - Payment Commission Data Act of 2019\nH.R. 938 - the BLOCKING Act of 2019\nH.R. 1520 - the Purple Book Continuity Act of 2019\nH.R. 1503 - the Orange Book Transparency Act of 2019\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 965 - the CREATES Act of 2019\nS. 1416 - Affordable Prescriptions For Patients Act of 2019 \nS. 1895 - Lower Health Care Costs Act \nH.R. 3 - Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act\nS. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act\nS. 3129 - Lower Costs, More Cures Act of 2019\n\nno specific bills, health care reform, Biosimilars, FDA policies, Innovation, 340B, comparative effectiveness research, non-interference, opioids","deficit reduction, debt ceiling, appropriations\nH.R. 4378 - Continuing Appropriations Act and Health Extenders Act\nH.R. 1865 - Further Consolidated Appropriations Act, 2020\nH.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act"],"years":[2018,2019,2020,2021,2022,2024,2025]}